董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin D. McNulty Jr. | 男 | Chief Executive Officer and Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Gavin Molinelli | 男 | Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Isaac T. Kohlberg | 男 | Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Maureen O' Connell | 女 | Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Geoffrey Ribar | 男 | Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Ajay Sundar | -- | Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Katharine Wolanyk | 女 | Director | -- | 未披露 | 未持股 | 2024-03-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin D. McNulty Jr. | 男 | Chief Executive Officer and Director | -- | 未披露 | 未持股 | 2024-03-15 |
| Jason Soncini | 男 | General Counsel | -- | 未披露 | 未持股 | 2024-03-15 |
| Robert Rasamny | -- | Chief Administrative Officer | -- | 未披露 | 未持股 | 2024-03-15 |
| Kirsten Hoover | 女 | Interim Chief Financial Officer | -- | 未披露 | 未持股 | 2024-03-15 |
董事简历
中英对照 | 中文 | 英文- Martin D. McNulty Jr.
-
Martin D. McNulty Jr.自2022年10月起担任我们的临时首席执行官。McNulty先生于2022年3月10日加入Acacia，担任首席运营官和并购主管。在加入Acacia之前，McNulty先生是Starboard Value Acquisition Corp（“SVAC”）的首席执行官，在2020年6月至2021年8月期间，他领导了SVAC与Cyxtera Technologies Inc.（纳斯达克股票代码：CYXT）合并的交易。McNulty先生还从2020年6月起担任Starboard的董事总经理，直到加入Acacia。从2013年9月到2020年5月，McNulty先生担任Starr Investment Holdings LLC的董事总经理和投资委员会成员，该公司是C.V. Starr and Co.的直接私募股权投资部门，负责寻找、执行和投资组合管理商业服务和医疗保健领域的投资机会，重点是支持拥有高超领导团队的市场领先公司发展业务。McNulty先生还曾担任Metalmark Capital Holdings，LLC的副总裁，该公司是一家以价值为导向的中间市场私募股权基金，专注于对医疗保健、工业和能源领域进行投资。从2004年到2007年，McNulty先生是Sum Capital Partners的高级合伙人，这是一家以价值为导向的中间市场私募股权基金，专注于对业务进行投资，其运营专业知识可以在表现不佳和扭亏为盈的情况下推动有意义的价值。麦克纳尔蒂的职业生涯始于普华永道会计师事务所的交易业务，在其整个职业生涯中曾担任多家私营公司的董事或董事会观察员。McNulty先生拥有爱荷华大学工商管理学士学位。
Martin D. McNulty Jr. has served as Acacia Research Corporation Interim Chief Executive Officer since October 2022. Mr. McNulty joined Acacia as Chief Operating Officer and Head of M&A on March 10, 2022. Prior to joining Acacia, Mr. McNulty was the Chief Executive Officer of Starboard Value Acquisition Corp ("SVAC"), where he led the transaction through which SVAC combined with Cyxtera Technologies Inc. (NASDAQ: CYXT) from June 2020 until August 2021. Mr. McNulty also served as a Managing Director of Starboard from June 2020 until joining Acacia. From September 2013 until May 2020, Mr. McNulty was a Managing Director and member of the investment committee at Starr Investment Holdings LLC, the direct private equity investment arm for C.V. Starr and Co., where he was responsible for sourcing, execution and portfolio management of investment opportunities in the business services and healthcare sectors with a focus on supporting market leading companies with superb leadership teams grow their businesses. Mr. McNulty has also served as Vice President at Metalmark Capital Holdings, LLC, a value-oriented middle market private equity fund focused on making investments in the healthcare, industrial, and energy sectors. From 2004 until 2007, Mr. McNulty was a Senior Associate at Sum Capital Partners, a value-oriented middle market private equity fund focused on making investments in business where its operational expertise could drive meaningful value in underperforming and turnaround situations. Mr. McNulty began his career in the Deals practice at PricewaterhouseCoopers and has served as a director or board observer of several private companies throughout his career. Mr. McNulty holds a B.B.A. in Business Administration from the University of Iowa. - Martin D. McNulty Jr.自2022年10月起担任我们的临时首席执行官。McNulty先生于2022年3月10日加入Acacia，担任首席运营官和并购主管。在加入Acacia之前，McNulty先生是Starboard Value Acquisition Corp（“SVAC”）的首席执行官，在2020年6月至2021年8月期间，他领导了SVAC与Cyxtera Technologies Inc.（纳斯达克股票代码：CYXT）合并的交易。McNulty先生还从2020年6月起担任Starboard的董事总经理，直到加入Acacia。从2013年9月到2020年5月，McNulty先生担任Starr Investment Holdings LLC的董事总经理和投资委员会成员，该公司是C.V. Starr and Co.的直接私募股权投资部门，负责寻找、执行和投资组合管理商业服务和医疗保健领域的投资机会，重点是支持拥有高超领导团队的市场领先公司发展业务。McNulty先生还曾担任Metalmark Capital Holdings，LLC的副总裁，该公司是一家以价值为导向的中间市场私募股权基金，专注于对医疗保健、工业和能源领域进行投资。从2004年到2007年，McNulty先生是Sum Capital Partners的高级合伙人，这是一家以价值为导向的中间市场私募股权基金，专注于对业务进行投资，其运营专业知识可以在表现不佳和扭亏为盈的情况下推动有意义的价值。麦克纳尔蒂的职业生涯始于普华永道会计师事务所的交易业务，在其整个职业生涯中曾担任多家私营公司的董事或董事会观察员。McNulty先生拥有爱荷华大学工商管理学士学位。
- Martin D. McNulty Jr. has served as Acacia Research Corporation Interim Chief Executive Officer since October 2022. Mr. McNulty joined Acacia as Chief Operating Officer and Head of M&A on March 10, 2022. Prior to joining Acacia, Mr. McNulty was the Chief Executive Officer of Starboard Value Acquisition Corp ("SVAC"), where he led the transaction through which SVAC combined with Cyxtera Technologies Inc. (NASDAQ: CYXT) from June 2020 until August 2021. Mr. McNulty also served as a Managing Director of Starboard from June 2020 until joining Acacia. From September 2013 until May 2020, Mr. McNulty was a Managing Director and member of the investment committee at Starr Investment Holdings LLC, the direct private equity investment arm for C.V. Starr and Co., where he was responsible for sourcing, execution and portfolio management of investment opportunities in the business services and healthcare sectors with a focus on supporting market leading companies with superb leadership teams grow their businesses. Mr. McNulty has also served as Vice President at Metalmark Capital Holdings, LLC, a value-oriented middle market private equity fund focused on making investments in the healthcare, industrial, and energy sectors. From 2004 until 2007, Mr. McNulty was a Senior Associate at Sum Capital Partners, a value-oriented middle market private equity fund focused on making investments in business where its operational expertise could drive meaningful value in underperforming and turnaround situations. Mr. McNulty began his career in the Deals practice at PricewaterhouseCoopers and has served as a director or board observer of several private companies throughout his career. Mr. McNulty holds a B.B.A. in Business Administration from the University of Iowa.
- Gavin Molinelli
-
加文·莫利内利自2022年10月起担任董事会主席和董事。目前，Molinelli先生是Starboard Value LP（“Starboard”）的合伙人兼联合投资组合经理，该公司是一家总部位于纽约的投资顾问，主要以专注和基本的方法投资于美国上市公司。在Starboard于2011年成立之前，作为分拆的一部分，Molinelli先生是Ramius LLC的董事和投资分析师，负责组成价值和机会投资平台的基金。在2006年10月加入Ramius LLC之前，Molinelli先生是美国银行证券有限责任公司技术投资银行组的成员。Molinelli先生此前曾于2018年4月至2018年12月被Brookfield Asset Management Inc. Asset Management Inc.（NYSE：BAM）收购之前，在Forest City Realty Trust, Inc.（前NYSE：FCEA）-一家房地产投资信托基金-的董事会任职；Depomed，Inc.（n/k/a Assertio Therapeutics, Inc.，Inc.（NASDAQ：ASRT）-一家专业制药公司-于2017年3月至2017年8月，在Wausau Paper Corp.（前NYSE：WPP）-一家当时领先的非居家毛巾和纸巾产品供应商-的董事会任职，自2014年7月至2016年1月被SCA Tissue North America LLC收购。Molinelli先生此前还曾在半导体公司Actel Corporation（前纳斯达克股票代码：ACTL）的董事会任职。Molinelli先生获得了华盛顿和李大学的经济学学士学位。
Gavin Molinelli has served as Chairman of the Board and a director since October 2022. Currently, Mr. Molinelli is a Partner and Co-Portfolio Manager of Starboard Value LP ("Starboard"), a New York-based investment adviser with a focused and fundamental approach to investing primarily in publicly traded U.S. companies. Prior to Starboard's formation in 2011, as part of a spin-off, Mr. Molinelli was a Director and an Investment Analyst at Ramius LLC for the funds that comprised the Value and Opportunity investment platform. Prior to joining Ramius LLC in October 2006, Mr. Molinelli was a member of the Technology Investment Banking group at Banc of America Securities LLC. Mr. Molinelli previously served on the Board of Directors of each of Forest City Realty Trust, Inc. (formerly NYSE: FCEA), a real estate investment trust, from April 2018 until its acquisition by Brookfield Asset Management Inc. (NYSE: BAM) in December 2018, Depomed, Inc. (n/k/a Assertio Therapeutics, Inc. (NASDAQ: ASRT)), a specialty pharmaceutical company, from March 2017 to August 2017 and Wausau Paper Corp. (formerly NYSE: WPP), a then leading provider of away from home towel and tissue products, from July 2014 until it was acquired by SCA Tissue North America LLC in January 2016. Mr. Molinelli also previously served on the Board of Directors of Actel Corporation (formerly NASDAQ: ACTL), a semiconductor company. Mr. Molinelli received a B.A. in Economics from Washington and Lee University. - 加文·莫利内利自2022年10月起担任董事会主席和董事。目前，Molinelli先生是Starboard Value LP（“Starboard”）的合伙人兼联合投资组合经理，该公司是一家总部位于纽约的投资顾问，主要以专注和基本的方法投资于美国上市公司。在Starboard于2011年成立之前，作为分拆的一部分，Molinelli先生是Ramius LLC的董事和投资分析师，负责组成价值和机会投资平台的基金。在2006年10月加入Ramius LLC之前，Molinelli先生是美国银行证券有限责任公司技术投资银行组的成员。Molinelli先生此前曾于2018年4月至2018年12月被Brookfield Asset Management Inc. Asset Management Inc.（NYSE：BAM）收购之前，在Forest City Realty Trust, Inc.（前NYSE：FCEA）-一家房地产投资信托基金-的董事会任职；Depomed，Inc.（n/k/a Assertio Therapeutics, Inc.，Inc.（NASDAQ：ASRT）-一家专业制药公司-于2017年3月至2017年8月，在Wausau Paper Corp.（前NYSE：WPP）-一家当时领先的非居家毛巾和纸巾产品供应商-的董事会任职，自2014年7月至2016年1月被SCA Tissue North America LLC收购。Molinelli先生此前还曾在半导体公司Actel Corporation（前纳斯达克股票代码：ACTL）的董事会任职。Molinelli先生获得了华盛顿和李大学的经济学学士学位。
- Gavin Molinelli has served as Chairman of the Board and a director since October 2022. Currently, Mr. Molinelli is a Partner and Co-Portfolio Manager of Starboard Value LP ("Starboard"), a New York-based investment adviser with a focused and fundamental approach to investing primarily in publicly traded U.S. companies. Prior to Starboard's formation in 2011, as part of a spin-off, Mr. Molinelli was a Director and an Investment Analyst at Ramius LLC for the funds that comprised the Value and Opportunity investment platform. Prior to joining Ramius LLC in October 2006, Mr. Molinelli was a member of the Technology Investment Banking group at Banc of America Securities LLC. Mr. Molinelli previously served on the Board of Directors of each of Forest City Realty Trust, Inc. (formerly NYSE: FCEA), a real estate investment trust, from April 2018 until its acquisition by Brookfield Asset Management Inc. (NYSE: BAM) in December 2018, Depomed, Inc. (n/k/a Assertio Therapeutics, Inc. (NASDAQ: ASRT)), a specialty pharmaceutical company, from March 2017 to August 2017 and Wausau Paper Corp. (formerly NYSE: WPP), a then leading provider of away from home towel and tissue products, from July 2014 until it was acquired by SCA Tissue North America LLC in January 2016. Mr. Molinelli also previously served on the Board of Directors of Actel Corporation (formerly NASDAQ: ACTL), a semiconductor company. Mr. Molinelli received a B.A. in Economics from Washington and Lee University.
- Isaac T. Kohlberg
-
Isaac T. Kohlberg自2019年5月起担任董事。科尔伯格先生在推动创业和创新，以及通过公司交易和初创企业组建保护知识产权（“IP”）和将其商业化方面有着卓越的职业生涯。他目前是哈佛大学的高级副教务长和首席技术开发官，负责哈佛研究企业产生的所有技术和IP的战略管理和商业开发。科尔伯格先生在哈佛大学的角色包括行业联络和外联、知识产权管理、商业发展、技术商业化以及围绕哈佛研发平台组建初创公司和新企业。同时，他还负责与业界建立、构建、谈判研究联盟和合作，并为哈佛教职员工筹集行业资助的研究资金。在2005年加入哈佛大学之前，科尔伯格先生是特拉维夫大学经济公司的首席执行官，也是该公司技术转让组织Ramot的负责人。在拉莫特任职之前，科尔伯格先生曾在纽约大学（“纽约大学”）担任过多个职务，包括副教务长、工业联络（纽约大学的技术转让项目）副总裁，并领导纽约大学医学院的科学和技术管理办公室。在他任职纽约大学期间，该机构签订了一项重要的许可协议，以开发Remicade，这是一种用于治疗克罗恩病和其他自身免疫性疾病的人源化单克隆抗体，这导致了全球任何一所大学产生的最大的特许权使用费收入流之一。在1989年加入纽约大学之前，科尔伯格先生是以色列魏茨曼科学研究所的商业部门YEDA的首席执行官。在YEDA期间，科尔伯格先生谈判并达成了主要的版税许可协议。几个例子包括与梯瓦制药有限公司就Copaxone达成的协议，Teva Pharmaceuticals将其作为复发/缓解多发性硬化症的专有治疗药物进行销售，以及与广播加密公司NDS Group达成的协议。Kohlberg先生自2021年5月起担任生物技术投资公司Arix Bioscience PLC（LON：ARIX）的董事。此外，科尔伯格先生于2017年2月至2021年3月期间担任关键阶段生物制药公司Anchiano Therapeutics Ltd（TLV：ANCN，NASDAQ：ANCN）的董事，并于2015年2月至2020年5月期间担任生命科学投资公司Clal Biotechnology Industries Ltd.（TLV：CBI）的董事。Kohlberg先生还于2014年2月至2021年4月担任临床阶段生物技术公司Elicio Therapeutics的董事。Kohlberg先生获得了欧洲工商管理学院的MBA学位和特拉维夫大学的法学学士学位。他还获得了斯特拉斯堡大学的法国文化和历史研究文凭。
Isaac T. Kohlberg has served as a director since May 2019. Mr. Kohlberg has had a distinguished career in advancing entrepreneurship and innovation, and protecting and commercializing intellectual property ("IP") through corporate deals and startup formation. He currently is a Senior Associate Provost and Chief Technology Development Officer at Harvard University, where he is responsible for the strategic management and commercial development of all technologies and IP arising from Harvard's research enterprise. Mr. Kohlberg's role at Harvard University includes industry liaising and outreach, IP Management, business development, technology commercialization and the formation of startup companies and new ventures around Harvard research and development platforms. In tandem, he is also responsible for generating, structuring, and negotiating research alliances and collaborations with industry and generating industry-sponsored research funding for Harvard faculty. Prior to joining Harvard in 2005, Mr. Kohlberg was the CEO of Tel Aviv University's Economic Corporation and head of Ramot, its technology transfer organization. Prior to his role at Ramot, Mr. Kohlberg held various roles at New York University ("NYU"), including Vice Provost, Vice President for Industrial Liaison (NYU's technology transfer program) and headed the Office of Science and Technology Administration at NYU School of Medicine. During his time at NYU, the institution entered into a major licensing agreement to develop Remicade, a humanized monoclonal antibody used in treatment of Crohn's Disease and other autoimmune diseases, which led to one of the largest royalty revenue streams generated by any university worldwide. Before joining NYU in 1989, Mr.Kohlberg was the CEO of YEDA, the commercial arm of the Weizmann Institute of Science in Israel. While at YEDA, Mr. Kohlberg negotiated and concluded major royalty-bearing license agreements. A few examples are an agreement with Teva Pharmaceutical Industries Ltd regarding Copaxone, which Teva Pharmaceuticals markets as a proprietary treatment for relapsing/remitting multiple sclerosis, and an agreement with the broadcasting encryption company NDS Group. Mr. Kohlberg has served as a Director at Arix Bioscience PLC (LON: ARIX), a biotechnology investment company, since May 2021. Additionally, Mr. Kohlberg has served as a Director at Anchiano Therapeutics Ltd (TLV: ANCN, NASDAQ: ANCN), a pivotal-stage biopharmaceutical company, from February 2017 through March 2021. and as a Director at Clal Biotechnology Industries Ltd. (TLV: CBI), a life sciences investment company, from February 2015 through May 2020. Mr. Kohlberg also served as a Director of Elicio Therapeutics, a clinical stage biotechnology company, from February 2014 through April 2021. Mr. Kohlberg received his MBA from INSEAD and LLB from Tel Aviv University. He also received a diploma in French culture and historical studies from the University of Strasbourg. - Isaac T. Kohlberg自2019年5月起担任董事。科尔伯格先生在推动创业和创新，以及通过公司交易和初创企业组建保护知识产权（“IP”）和将其商业化方面有着卓越的职业生涯。他目前是哈佛大学的高级副教务长和首席技术开发官，负责哈佛研究企业产生的所有技术和IP的战略管理和商业开发。科尔伯格先生在哈佛大学的角色包括行业联络和外联、知识产权管理、商业发展、技术商业化以及围绕哈佛研发平台组建初创公司和新企业。同时，他还负责与业界建立、构建、谈判研究联盟和合作，并为哈佛教职员工筹集行业资助的研究资金。在2005年加入哈佛大学之前，科尔伯格先生是特拉维夫大学经济公司的首席执行官，也是该公司技术转让组织Ramot的负责人。在拉莫特任职之前，科尔伯格先生曾在纽约大学（“纽约大学”）担任过多个职务，包括副教务长、工业联络（纽约大学的技术转让项目）副总裁，并领导纽约大学医学院的科学和技术管理办公室。在他任职纽约大学期间，该机构签订了一项重要的许可协议，以开发Remicade，这是一种用于治疗克罗恩病和其他自身免疫性疾病的人源化单克隆抗体，这导致了全球任何一所大学产生的最大的特许权使用费收入流之一。在1989年加入纽约大学之前，科尔伯格先生是以色列魏茨曼科学研究所的商业部门YEDA的首席执行官。在YEDA期间，科尔伯格先生谈判并达成了主要的版税许可协议。几个例子包括与梯瓦制药有限公司就Copaxone达成的协议，Teva Pharmaceuticals将其作为复发/缓解多发性硬化症的专有治疗药物进行销售，以及与广播加密公司NDS Group达成的协议。Kohlberg先生自2021年5月起担任生物技术投资公司Arix Bioscience PLC（LON：ARIX）的董事。此外，科尔伯格先生于2017年2月至2021年3月期间担任关键阶段生物制药公司Anchiano Therapeutics Ltd（TLV：ANCN，NASDAQ：ANCN）的董事，并于2015年2月至2020年5月期间担任生命科学投资公司Clal Biotechnology Industries Ltd.（TLV：CBI）的董事。Kohlberg先生还于2014年2月至2021年4月担任临床阶段生物技术公司Elicio Therapeutics的董事。Kohlberg先生获得了欧洲工商管理学院的MBA学位和特拉维夫大学的法学学士学位。他还获得了斯特拉斯堡大学的法国文化和历史研究文凭。
- Isaac T. Kohlberg has served as a director since May 2019. Mr. Kohlberg has had a distinguished career in advancing entrepreneurship and innovation, and protecting and commercializing intellectual property ("IP") through corporate deals and startup formation. He currently is a Senior Associate Provost and Chief Technology Development Officer at Harvard University, where he is responsible for the strategic management and commercial development of all technologies and IP arising from Harvard's research enterprise. Mr. Kohlberg's role at Harvard University includes industry liaising and outreach, IP Management, business development, technology commercialization and the formation of startup companies and new ventures around Harvard research and development platforms. In tandem, he is also responsible for generating, structuring, and negotiating research alliances and collaborations with industry and generating industry-sponsored research funding for Harvard faculty. Prior to joining Harvard in 2005, Mr. Kohlberg was the CEO of Tel Aviv University's Economic Corporation and head of Ramot, its technology transfer organization. Prior to his role at Ramot, Mr. Kohlberg held various roles at New York University ("NYU"), including Vice Provost, Vice President for Industrial Liaison (NYU's technology transfer program) and headed the Office of Science and Technology Administration at NYU School of Medicine. During his time at NYU, the institution entered into a major licensing agreement to develop Remicade, a humanized monoclonal antibody used in treatment of Crohn's Disease and other autoimmune diseases, which led to one of the largest royalty revenue streams generated by any university worldwide. Before joining NYU in 1989, Mr.Kohlberg was the CEO of YEDA, the commercial arm of the Weizmann Institute of Science in Israel. While at YEDA, Mr. Kohlberg negotiated and concluded major royalty-bearing license agreements. A few examples are an agreement with Teva Pharmaceutical Industries Ltd regarding Copaxone, which Teva Pharmaceuticals markets as a proprietary treatment for relapsing/remitting multiple sclerosis, and an agreement with the broadcasting encryption company NDS Group. Mr. Kohlberg has served as a Director at Arix Bioscience PLC (LON: ARIX), a biotechnology investment company, since May 2021. Additionally, Mr. Kohlberg has served as a Director at Anchiano Therapeutics Ltd (TLV: ANCN, NASDAQ: ANCN), a pivotal-stage biopharmaceutical company, from February 2017 through March 2021. and as a Director at Clal Biotechnology Industries Ltd. (TLV: CBI), a life sciences investment company, from February 2015 through May 2020. Mr. Kohlberg also served as a Director of Elicio Therapeutics, a clinical stage biotechnology company, from February 2014 through April 2021. Mr. Kohlberg received his MBA from INSEAD and LLB from Tel Aviv University. He also received a diploma in French culture and historical studies from the University of Strasbourg.
- Maureen O' Connell
-
莫琳·奥康奈尔自2019年1月起担任董事。在加入Acacia之前，O'Connell女士曾于2018年9月至2018年11月期间为公司短暂提供过咨询服务。O’Connell女士是一名全球业务主管、首席财务官和董事会董事，因在众多上市公司通过战略思考和行动创造了重大价值而受到认可。她曾在多个行业担任行政领导和董事会职务，包括媒体、教育、数字、零售、技术、专业服务、生物技术、制药、房屋建筑、房地产和保险。她曾担任审计委员会主席，在交易和提名委员会任职，并担任《财富》500强和纽交所和纳斯达克上市的高增长上市公司的指定财务专家。此外，O’Connell女士是一名注册会计师，自1987年以来一直信誉良好。奥康奈尔女士还因其丰富的并购经验以及在运营和技术方面的实力而受到认可。O’Connell女士于2020年6月被任命为非营利公司ISACA的董事会成员，O’Connell女士于2021年5月被任命为生命科学投资公司Arix Bioscience PLC的董事会成员。O’Connell女士目前还担任私人控股公司HH Global Ltd.的董事会成员，并担任审计委员会主席。O’Connell女士于2018年6月至2020年8月期间担任哈特-汉克斯（NYSE：HHS）的董事会成员。O’Connell女士还是哈特-汉克斯审计委员会和薪酬委员会的成员。O’Connell女士于2013年至2018年在快速增长的生物技术公司苏卡波制药 Inc.（NASDAQ：SCMP）的董事会任职。在2018年2月以12亿美元将其出售给马林克罗制药有限公司的交易中，她发挥了关键作用。从2007年到2017年，O'Connell女士担任Scholastic，Inc.的执行副总裁、首席行政官和首席财务官，Scholastic，Inc.是一家知名的童书出版商和分销商，也是教育技术和儿童媒体的领先公司。从2002年到2007年，奥康奈尔女士担任Beazer Homes（NYSE：BZH）的董事会成员，该公司是一家财富500强的住宅建筑商。最初，奥康奈尔女士在Beazer Homes的审计和薪酬委员会任职，并于2003年被任命为审计主席。奥康奈尔女士是全国公司董事协会认证董事。
Maureen O' Connell has served as a director since January 2019. Prior to joining Acacia, Ms. O'Connell briefly provided consulting services to the Company from September 2018 to November 2018. Ms. O'Connell is a global business executive, CFO and board director recognized for significant value creation through strategic thinking and action at numerous public companies. She has held executive leadership and board positions in a variety of industries including media, education, digital, retail, technology, professional services, biotech, pharma, homebuilding, real estate and insurance. She has chaired the Audit Committee, served on the Transaction and Nominating Committees, and served as the designated financial expert for Fortune 500 and high growth public companies listed on NYSE and NASDAQ. In addition, Ms. O'Connell is a certified public accountant and has been in good standing since 1987. Ms. O'Connell is also recognized for her extensive M&A experience and her strength in operations and technology. Ms. O'Connell was appointed to the Board of ISACA, a non-profit company, in June 2020 and Ms. O'Connell was appointed to the Board of Arix Bioscience PLC, a life sciences investment company, in May 2021. Ms. O'Connell is also currently serving on the Board of HH Global Ltd., a privately held company, and is chair of the Audit Committee. Ms. O'Connell served on the Board of Harte Hanks (NYSE: HHS) from June 2018 to August 2020. Ms. O'Connell was also a member of the Audit Committee and Compensation Committee of Harte Hanks. Ms. O'Connell served on the Board of Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), a fast growth biotech company, from 2013 to 2018. She played a key role in its sale to Mallinckrodt Plc for $1.2 billion in February 2018. From 2007 to 2017, Ms. O'Connell has served as Executive Vice President, Chief Administrative Officer and Chief Financial Officer of Scholastic, Inc., a well-known publisher and distributor of children's books and a leading company in educational technology and children's media. From 2002 to 2007, Ms. O'Connell served on the Board of Beazer Homes (NYSE: BZH), a Fortune 500 homebuilder. Initially, Ms. O'Connell served on the Audit and Compensation Committees of Beazer Homes and in 2003 was named Audit Chair. Ms. O'Connell is a National Association of Corporate Directors certified Director. - 莫琳·奥康奈尔自2019年1月起担任董事。在加入Acacia之前，O'Connell女士曾于2018年9月至2018年11月期间为公司短暂提供过咨询服务。O’Connell女士是一名全球业务主管、首席财务官和董事会董事，因在众多上市公司通过战略思考和行动创造了重大价值而受到认可。她曾在多个行业担任行政领导和董事会职务，包括媒体、教育、数字、零售、技术、专业服务、生物技术、制药、房屋建筑、房地产和保险。她曾担任审计委员会主席，在交易和提名委员会任职，并担任《财富》500强和纽交所和纳斯达克上市的高增长上市公司的指定财务专家。此外，O’Connell女士是一名注册会计师，自1987年以来一直信誉良好。奥康奈尔女士还因其丰富的并购经验以及在运营和技术方面的实力而受到认可。O’Connell女士于2020年6月被任命为非营利公司ISACA的董事会成员，O’Connell女士于2021年5月被任命为生命科学投资公司Arix Bioscience PLC的董事会成员。O’Connell女士目前还担任私人控股公司HH Global Ltd.的董事会成员，并担任审计委员会主席。O’Connell女士于2018年6月至2020年8月期间担任哈特-汉克斯（NYSE：HHS）的董事会成员。O’Connell女士还是哈特-汉克斯审计委员会和薪酬委员会的成员。O’Connell女士于2013年至2018年在快速增长的生物技术公司苏卡波制药 Inc.（NASDAQ：SCMP）的董事会任职。在2018年2月以12亿美元将其出售给马林克罗制药有限公司的交易中，她发挥了关键作用。从2007年到2017年，O'Connell女士担任Scholastic，Inc.的执行副总裁、首席行政官和首席财务官，Scholastic，Inc.是一家知名的童书出版商和分销商，也是教育技术和儿童媒体的领先公司。从2002年到2007年，奥康奈尔女士担任Beazer Homes（NYSE：BZH）的董事会成员，该公司是一家财富500强的住宅建筑商。最初，奥康奈尔女士在Beazer Homes的审计和薪酬委员会任职，并于2003年被任命为审计主席。奥康奈尔女士是全国公司董事协会认证董事。
- Maureen O' Connell has served as a director since January 2019. Prior to joining Acacia, Ms. O'Connell briefly provided consulting services to the Company from September 2018 to November 2018. Ms. O'Connell is a global business executive, CFO and board director recognized for significant value creation through strategic thinking and action at numerous public companies. She has held executive leadership and board positions in a variety of industries including media, education, digital, retail, technology, professional services, biotech, pharma, homebuilding, real estate and insurance. She has chaired the Audit Committee, served on the Transaction and Nominating Committees, and served as the designated financial expert for Fortune 500 and high growth public companies listed on NYSE and NASDAQ. In addition, Ms. O'Connell is a certified public accountant and has been in good standing since 1987. Ms. O'Connell is also recognized for her extensive M&A experience and her strength in operations and technology. Ms. O'Connell was appointed to the Board of ISACA, a non-profit company, in June 2020 and Ms. O'Connell was appointed to the Board of Arix Bioscience PLC, a life sciences investment company, in May 2021. Ms. O'Connell is also currently serving on the Board of HH Global Ltd., a privately held company, and is chair of the Audit Committee. Ms. O'Connell served on the Board of Harte Hanks (NYSE: HHS) from June 2018 to August 2020. Ms. O'Connell was also a member of the Audit Committee and Compensation Committee of Harte Hanks. Ms. O'Connell served on the Board of Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), a fast growth biotech company, from 2013 to 2018. She played a key role in its sale to Mallinckrodt Plc for $1.2 billion in February 2018. From 2007 to 2017, Ms. O'Connell has served as Executive Vice President, Chief Administrative Officer and Chief Financial Officer of Scholastic, Inc., a well-known publisher and distributor of children's books and a leading company in educational technology and children's media. From 2002 to 2007, Ms. O'Connell served on the Board of Beazer Homes (NYSE: BZH), a Fortune 500 homebuilder. Initially, Ms. O'Connell served on the Audit and Compensation Committees of Beazer Homes and in 2003 was named Audit Chair. Ms. O'Connell is a National Association of Corporate Directors certified Director.
- Geoffrey Ribar
-
Geoffrey Ribar已被提名参加年会的董事会选举。Ribar先生目前担任自2017年3月起担任电信、工业和国防以及数据中心行业半导体产品的设计者和制造商MACOM Technology解决方案控股公司的董事，以及自2017年3月起担任分立和嵌入式磁阻RAM（MRAM）和自旋转移扭矩MRAM（STT-MRAM）技术的开发商和制造商Everspin Technologies, Inc.的董事。此前Ribar先生于2017年9月至2019年9月被迈威尔科技收购之前，曾担任用于以太网连接的高速通信集成电路提供商Aquantia Corp.的董事。Ribar先生于2010年11月至2017年9月期间在系统设计工具、软件、知识产权和服务提供商铿腾电子科技有限公司（“Cadence”）担任高级副总裁兼首席财务官，并担任Cadence的高级顾问至2018年3月退休。此前，他曾在多家半导体公司担任首席财务官，包括Telegent Systems，Inc.、SiRF Technology，Inc.、ASYST Technology，Inc.、Matrix Semiconductor，Inc.和nVidia Corporation。他获得了密歇根大学化学学士学位和工商管理硕士学位。
Geoffrey Ribar has been nominated for election to the Board at the Annual Meeting. Mr. Ribar currently serves as a director of MACOM Technology Solutions Holdings, Inc., a designer and manufacturer of semiconductor products for Telecommunications, Industrial and Defense and Data Center industries, a position he has held since March 2017, and as a director of Everspin Technologies, Inc., a developer and manufacturer of discrete and embedded Magnetoresistive RAM (MRAM) and Spin-transfer Torque MRAM (STT-MRAM) technologies, a position he has held since March 2017. Previously Mr. Ribar served as a director of Aquantia Corp., a provider of high-speed communications integrated circuits for Ethernet connectivity, from September 2017 until its acquisition by Marvell Technology in September 2019. Mr. Ribar served as Senior Vice President and Chief Financial Officer of Cadence Design Systems, Inc. ("Cadence"), a provider of system design tools, software, intellectual property and services, from November 2010 to September 2017, and acted as a senior advisor to Cadence until his retirement in March 2018. Previously, he served as Chief Financial Officer for a number of semiconductor companies, including Telegent Systems, Inc., SiRF Technology, Inc., Asyst Technology, Inc., Matrix Semiconductor, Inc. and nVidia Corporation. He received his B.S. degree in chemistry and an M.B.A. from the University of Michigan. - Geoffrey Ribar已被提名参加年会的董事会选举。Ribar先生目前担任自2017年3月起担任电信、工业和国防以及数据中心行业半导体产品的设计者和制造商MACOM Technology解决方案控股公司的董事，以及自2017年3月起担任分立和嵌入式磁阻RAM（MRAM）和自旋转移扭矩MRAM（STT-MRAM）技术的开发商和制造商Everspin Technologies, Inc.的董事。此前Ribar先生于2017年9月至2019年9月被迈威尔科技收购之前，曾担任用于以太网连接的高速通信集成电路提供商Aquantia Corp.的董事。Ribar先生于2010年11月至2017年9月期间在系统设计工具、软件、知识产权和服务提供商铿腾电子科技有限公司（“Cadence”）担任高级副总裁兼首席财务官，并担任Cadence的高级顾问至2018年3月退休。此前，他曾在多家半导体公司担任首席财务官，包括Telegent Systems，Inc.、SiRF Technology，Inc.、ASYST Technology，Inc.、Matrix Semiconductor，Inc.和nVidia Corporation。他获得了密歇根大学化学学士学位和工商管理硕士学位。
- Geoffrey Ribar has been nominated for election to the Board at the Annual Meeting. Mr. Ribar currently serves as a director of MACOM Technology Solutions Holdings, Inc., a designer and manufacturer of semiconductor products for Telecommunications, Industrial and Defense and Data Center industries, a position he has held since March 2017, and as a director of Everspin Technologies, Inc., a developer and manufacturer of discrete and embedded Magnetoresistive RAM (MRAM) and Spin-transfer Torque MRAM (STT-MRAM) technologies, a position he has held since March 2017. Previously Mr. Ribar served as a director of Aquantia Corp., a provider of high-speed communications integrated circuits for Ethernet connectivity, from September 2017 until its acquisition by Marvell Technology in September 2019. Mr. Ribar served as Senior Vice President and Chief Financial Officer of Cadence Design Systems, Inc. ("Cadence"), a provider of system design tools, software, intellectual property and services, from November 2010 to September 2017, and acted as a senior advisor to Cadence until his retirement in March 2018. Previously, he served as Chief Financial Officer for a number of semiconductor companies, including Telegent Systems, Inc., SiRF Technology, Inc., Asyst Technology, Inc., Matrix Semiconductor, Inc. and nVidia Corporation. He received his B.S. degree in chemistry and an M.B.A. from the University of Michigan.
- Ajay Sundar
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Katharine Wolanyk
-
Katharine Wolanyk自2019年1月起担任董事。Wolanyk女士是伯福德资本有限责任公司的董事总经理，在那里她领导着Burford的IP业务，直到最近，她还领导着他们在芝加哥的办事处。Wolanyk女士的职业生涯横跨商业、法律和工程领域，尤其专注于知识产权。2015年至2022年，她被Intellectual Asset Management评为全球领先的知识产权策略师，并经常就知识产权问题进行写作和演讲。在2016年1月加入Burford之前，Wolanyk女士是Soverain Software的总裁、首席法务官和董事会成员，Soverain Software是一家企业软件公司，其专利组合已在软件和互联网零售行业获得广泛许可。Wolanyk女士还曾是上市IT解决方案公司即时服务器资源池的知识产权顾问、托管托管提供商Data Return LLC的总法律顾问、上市企业软件公司Divine，Inc.的企业发展高级副总裁、Latham & Watkins LLP的公司律师以及Hughes Aircraft Company的系统工程师。Wolanyk女士在芝加哥大学法学院获得了京东学位，并在密歇根州立大学获得了工程学学士学位。她曾在芝加哥大学法学院访问委员会和芝加哥大都会基督教青年会管理委员会任职。
Katharine Wolanyk has served as a director since January 2019. Ms. Wolanyk is a Managing Director at Burford Capital, LLC, where she leads Burford's IP business and, until recently, led their Chicago office. Ms. Wolanyk's career spans the business, legal and engineering arenas, with a particular focus in IP. She was named a World's Leading IP Strategist by Intellectual Asset Management in 2015 through 2022, and writes and speaks frequently on IP issues. Prior to joining Burford in January 2016, Ms. Wolanyk was President, Chief Legal Officer and a Board member of Soverain Software, an enterprise software company whose patent portfolio has been licensed extensively in the software and internet retailing industries. Ms. Wolanyk also was IP counsel to Terremark Worldwide, Inc., a publicly traded IT solutions firm, General Counsel of Data Return LLC, a managed hosting provider, Senior Vice President of corporate development at Divine, Inc., a publicly traded enterprise software company a corporate attorney at Latham & Watkins LLP, and a systems engineer at Hughes Aircraft Company. Ms. Wolanyk earned her JD from the University of Chicago Law School, and a BS in engineering from Michigan State University. She has served on the University of Chicago Law School Visiting Committee and on the Board of Managers of the YMCA of Metropolitan Chicago. - Katharine Wolanyk自2019年1月起担任董事。Wolanyk女士是伯福德资本有限责任公司的董事总经理，在那里她领导着Burford的IP业务，直到最近，她还领导着他们在芝加哥的办事处。Wolanyk女士的职业生涯横跨商业、法律和工程领域，尤其专注于知识产权。2015年至2022年，她被Intellectual Asset Management评为全球领先的知识产权策略师，并经常就知识产权问题进行写作和演讲。在2016年1月加入Burford之前，Wolanyk女士是Soverain Software的总裁、首席法务官和董事会成员，Soverain Software是一家企业软件公司，其专利组合已在软件和互联网零售行业获得广泛许可。Wolanyk女士还曾是上市IT解决方案公司即时服务器资源池的知识产权顾问、托管托管提供商Data Return LLC的总法律顾问、上市企业软件公司Divine，Inc.的企业发展高级副总裁、Latham & Watkins LLP的公司律师以及Hughes Aircraft Company的系统工程师。Wolanyk女士在芝加哥大学法学院获得了京东学位，并在密歇根州立大学获得了工程学学士学位。她曾在芝加哥大学法学院访问委员会和芝加哥大都会基督教青年会管理委员会任职。
- Katharine Wolanyk has served as a director since January 2019. Ms. Wolanyk is a Managing Director at Burford Capital, LLC, where she leads Burford's IP business and, until recently, led their Chicago office. Ms. Wolanyk's career spans the business, legal and engineering arenas, with a particular focus in IP. She was named a World's Leading IP Strategist by Intellectual Asset Management in 2015 through 2022, and writes and speaks frequently on IP issues. Prior to joining Burford in January 2016, Ms. Wolanyk was President, Chief Legal Officer and a Board member of Soverain Software, an enterprise software company whose patent portfolio has been licensed extensively in the software and internet retailing industries. Ms. Wolanyk also was IP counsel to Terremark Worldwide, Inc., a publicly traded IT solutions firm, General Counsel of Data Return LLC, a managed hosting provider, Senior Vice President of corporate development at Divine, Inc., a publicly traded enterprise software company a corporate attorney at Latham & Watkins LLP, and a systems engineer at Hughes Aircraft Company. Ms. Wolanyk earned her JD from the University of Chicago Law School, and a BS in engineering from Michigan State University. She has served on the University of Chicago Law School Visiting Committee and on the Board of Managers of the YMCA of Metropolitan Chicago.
高管简历
中英对照 | 中文 | 英文- Martin D. McNulty Jr.
Martin D. McNulty Jr.自2022年10月起担任我们的临时首席执行官。McNulty先生于2022年3月10日加入Acacia，担任首席运营官和并购主管。在加入Acacia之前，McNulty先生是Starboard Value Acquisition Corp（“SVAC”）的首席执行官，在2020年6月至2021年8月期间，他领导了SVAC与Cyxtera Technologies Inc.（纳斯达克股票代码：CYXT）合并的交易。McNulty先生还从2020年6月起担任Starboard的董事总经理，直到加入Acacia。从2013年9月到2020年5月，McNulty先生担任Starr Investment Holdings LLC的董事总经理和投资委员会成员，该公司是C.V. Starr and Co.的直接私募股权投资部门，负责寻找、执行和投资组合管理商业服务和医疗保健领域的投资机会，重点是支持拥有高超领导团队的市场领先公司发展业务。McNulty先生还曾担任Metalmark Capital Holdings，LLC的副总裁，该公司是一家以价值为导向的中间市场私募股权基金，专注于对医疗保健、工业和能源领域进行投资。从2004年到2007年，McNulty先生是Sum Capital Partners的高级合伙人，这是一家以价值为导向的中间市场私募股权基金，专注于对业务进行投资，其运营专业知识可以在表现不佳和扭亏为盈的情况下推动有意义的价值。麦克纳尔蒂的职业生涯始于普华永道会计师事务所的交易业务，在其整个职业生涯中曾担任多家私营公司的董事或董事会观察员。McNulty先生拥有爱荷华大学工商管理学士学位。
Martin D. McNulty Jr. has served as Acacia Research Corporation Interim Chief Executive Officer since October 2022. Mr. McNulty joined Acacia as Chief Operating Officer and Head of M&A on March 10, 2022. Prior to joining Acacia, Mr. McNulty was the Chief Executive Officer of Starboard Value Acquisition Corp ("SVAC"), where he led the transaction through which SVAC combined with Cyxtera Technologies Inc. (NASDAQ: CYXT) from June 2020 until August 2021. Mr. McNulty also served as a Managing Director of Starboard from June 2020 until joining Acacia. From September 2013 until May 2020, Mr. McNulty was a Managing Director and member of the investment committee at Starr Investment Holdings LLC, the direct private equity investment arm for C.V. Starr and Co., where he was responsible for sourcing, execution and portfolio management of investment opportunities in the business services and healthcare sectors with a focus on supporting market leading companies with superb leadership teams grow their businesses. Mr. McNulty has also served as Vice President at Metalmark Capital Holdings, LLC, a value-oriented middle market private equity fund focused on making investments in the healthcare, industrial, and energy sectors. From 2004 until 2007, Mr. McNulty was a Senior Associate at Sum Capital Partners, a value-oriented middle market private equity fund focused on making investments in business where its operational expertise could drive meaningful value in underperforming and turnaround situations. Mr. McNulty began his career in the Deals practice at PricewaterhouseCoopers and has served as a director or board observer of several private companies throughout his career. Mr. McNulty holds a B.B.A. in Business Administration from the University of Iowa.- Martin D. McNulty Jr.自2022年10月起担任我们的临时首席执行官。McNulty先生于2022年3月10日加入Acacia，担任首席运营官和并购主管。在加入Acacia之前，McNulty先生是Starboard Value Acquisition Corp（“SVAC”）的首席执行官，在2020年6月至2021年8月期间，他领导了SVAC与Cyxtera Technologies Inc.（纳斯达克股票代码：CYXT）合并的交易。McNulty先生还从2020年6月起担任Starboard的董事总经理，直到加入Acacia。从2013年9月到2020年5月，McNulty先生担任Starr Investment Holdings LLC的董事总经理和投资委员会成员，该公司是C.V. Starr and Co.的直接私募股权投资部门，负责寻找、执行和投资组合管理商业服务和医疗保健领域的投资机会，重点是支持拥有高超领导团队的市场领先公司发展业务。McNulty先生还曾担任Metalmark Capital Holdings，LLC的副总裁，该公司是一家以价值为导向的中间市场私募股权基金，专注于对医疗保健、工业和能源领域进行投资。从2004年到2007年，McNulty先生是Sum Capital Partners的高级合伙人，这是一家以价值为导向的中间市场私募股权基金，专注于对业务进行投资，其运营专业知识可以在表现不佳和扭亏为盈的情况下推动有意义的价值。麦克纳尔蒂的职业生涯始于普华永道会计师事务所的交易业务，在其整个职业生涯中曾担任多家私营公司的董事或董事会观察员。McNulty先生拥有爱荷华大学工商管理学士学位。
- Martin D. McNulty Jr. has served as Acacia Research Corporation Interim Chief Executive Officer since October 2022. Mr. McNulty joined Acacia as Chief Operating Officer and Head of M&A on March 10, 2022. Prior to joining Acacia, Mr. McNulty was the Chief Executive Officer of Starboard Value Acquisition Corp ("SVAC"), where he led the transaction through which SVAC combined with Cyxtera Technologies Inc. (NASDAQ: CYXT) from June 2020 until August 2021. Mr. McNulty also served as a Managing Director of Starboard from June 2020 until joining Acacia. From September 2013 until May 2020, Mr. McNulty was a Managing Director and member of the investment committee at Starr Investment Holdings LLC, the direct private equity investment arm for C.V. Starr and Co., where he was responsible for sourcing, execution and portfolio management of investment opportunities in the business services and healthcare sectors with a focus on supporting market leading companies with superb leadership teams grow their businesses. Mr. McNulty has also served as Vice President at Metalmark Capital Holdings, LLC, a value-oriented middle market private equity fund focused on making investments in the healthcare, industrial, and energy sectors. From 2004 until 2007, Mr. McNulty was a Senior Associate at Sum Capital Partners, a value-oriented middle market private equity fund focused on making investments in business where its operational expertise could drive meaningful value in underperforming and turnaround situations. Mr. McNulty began his career in the Deals practice at PricewaterhouseCoopers and has served as a director or board observer of several private companies throughout his career. Mr. McNulty holds a B.B.A. in Business Administration from the University of Iowa.
- Jason Soncini
Jason Soncini于2021年3月加入Acacia，担任总法律顾问。从2017年4月到加入Acacia，Soncini先生受雇于盛大集团，这是一家私营跨国投资公司，最初担任副总法律顾问，后来担任总法律顾问。2013年10月至2017年4月，Soncini先生担任Kleinberg，Kaplan，Wolff & 科恩，P.C.的律师。Soncini先生于2006年在Olshan Frome Wolosky LLP开始了他的法律生涯。Soncini先生拥有密歇根大学数学学士学位，并在西北大学获得法学博士学位。
Jason Soncini joined Acacia as its General Counsel in March 2021. From April 2017 until he joined Acacia, Mr. Soncini was employed at Shanda Group, a privately-owned multinational investment firm, initially as Deputy General Counsel and then as General Counsel. From October 2013 until April 2017, Mr. Soncini was an attorney at Kleinberg, Kaplan, Wolff & Cohen, P.C. Mr. Soncini began his legal career at Olshan Frome Wolosky LLP in 2006. Mr. Soncini holds a B.A. in Mathematics from the University of Michigan and received his J.D. from Northwestern University.- Jason Soncini于2021年3月加入Acacia，担任总法律顾问。从2017年4月到加入Acacia，Soncini先生受雇于盛大集团，这是一家私营跨国投资公司，最初担任副总法律顾问，后来担任总法律顾问。2013年10月至2017年4月，Soncini先生担任Kleinberg，Kaplan，Wolff & 科恩，P.C.的律师。Soncini先生于2006年在Olshan Frome Wolosky LLP开始了他的法律生涯。Soncini先生拥有密歇根大学数学学士学位，并在西北大学获得法学博士学位。
- Jason Soncini joined Acacia as its General Counsel in March 2021. From April 2017 until he joined Acacia, Mr. Soncini was employed at Shanda Group, a privately-owned multinational investment firm, initially as Deputy General Counsel and then as General Counsel. From October 2013 until April 2017, Mr. Soncini was an attorney at Kleinberg, Kaplan, Wolff & Cohen, P.C. Mr. Soncini began his legal career at Olshan Frome Wolosky LLP in 2006. Mr. Soncini holds a B.A. in Mathematics from the University of Michigan and received his J.D. from Northwestern University.
- Robert Rasamny
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Kirsten Hoover
Kirsten Hoover自2023年1月起担任本社临时首席财务官。她于2021年10月重新加入阿卡西亚，担任我们的财务总监。此前，她曾于2002年至2019年任职于Acacia，最近担任财务总监。她毕业于加州大学圣巴巴拉分校，获得经济学学位，随后加入德勤审计与鉴证部。2019年12月至2021年10月，她在Veritone公司担任财务报告高级经理。胡佛女士还担任水手小学基金会的财务主管。
Kirsten Hoover has served as Acacia Research Corporation Interim Chief Financial Officer since January 2023. She rejoined Acacia Research as Acacia Research Corporation Controller in October 2021. She was previously with Acacia from 2002 until 2019, most recently serving as Controller. She graduated from UC Santa Barbara with an Economics degree and subsequently joined Deloitte in Audit & Assurance. From December 2019 - October 2021 she was the Sr. Manager of Financial Reporting at Veritone Inc. Ms. Hoover also serves as Treasurer of the Mariners Elementary School Foundation.- Kirsten Hoover自2023年1月起担任本社临时首席财务官。她于2021年10月重新加入阿卡西亚，担任我们的财务总监。此前，她曾于2002年至2019年任职于Acacia，最近担任财务总监。她毕业于加州大学圣巴巴拉分校，获得经济学学位，随后加入德勤审计与鉴证部。2019年12月至2021年10月，她在Veritone公司担任财务报告高级经理。胡佛女士还担任水手小学基金会的财务主管。
- Kirsten Hoover has served as Acacia Research Corporation Interim Chief Financial Officer since January 2023. She rejoined Acacia Research as Acacia Research Corporation Controller in October 2021. She was previously with Acacia from 2002 until 2019, most recently serving as Controller. She graduated from UC Santa Barbara with an Economics degree and subsequently joined Deloitte in Audit & Assurance. From December 2019 - October 2021 she was the Sr. Manager of Financial Reporting at Veritone Inc. Ms. Hoover also serves as Treasurer of the Mariners Elementary School Foundation.